STRATA Skin Sciences Crecimiento futuro
Future controles de criterios 0/6
STRATA Skin Sciences is forecast to grow earnings and revenue by 39.7% and 7.3% per annum respectively while EPS is expected to grow by 47.8% per annum.
Información clave
39.7%
Tasa de crecimiento de los beneficios
47.8%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 17.4% |
| Tasa de crecimiento de los ingresos | 7.3% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 19 Aug 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%
Aug 18
Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?
Aug 07STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business
Jun 07Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?
Mar 19STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Dec 31Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?
Nov 03We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt
Jul 04STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company
Apr 18Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?
Jan 14STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M
Aug 10Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment
Jul 25What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Mar 09Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years
Nov 24
STRATA Skin Sciences EPS in-line, beats on revenue
Nov 10Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 40 | -2 | N/A | 7 | 1 |
| 12/31/2025 | 34 | -6 | N/A | 3 | 2 |
| 12/31/2024 | 33 | -7 | N/A | 0 | 1 |
| 6/30/2024 | 33 | -8 | -3 | -1 | N/A |
| 3/31/2024 | 33 | -11 | -4 | -1 | N/A |
| 12/31/2023 | 33 | -11 | -6 | -1 | N/A |
| 9/30/2023 | 35 | -7 | -6 | -1 | N/A |
| 6/30/2023 | 36 | -7 | -6 | 0 | N/A |
| 3/31/2023 | 37 | -6 | -6 | -1 | N/A |
| 12/31/2022 | 36 | -6 | -5 | -1 | N/A |
| 9/30/2022 | 35 | -6 | -4 | 0 | N/A |
| 6/30/2022 | 33 | -6 | -3 | 1 | N/A |
| 3/31/2022 | 31 | -3 | -3 | 1 | N/A |
| 12/31/2021 | 30 | -3 | -2 | 2 | N/A |
| 9/30/2021 | 28 | -2 | -2 | 1 | N/A |
| 6/30/2021 | 26 | -3 | -2 | 1 | N/A |
| 3/31/2021 | 22 | -6 | -1 | 2 | N/A |
| 12/31/2020 | 23 | -4 | 0 | 2 | N/A |
| 9/30/2020 | 25 | -4 | N/A | 3 | N/A |
| 6/30/2020 | 27 | -4 | 0 | 3 | N/A |
| 3/31/2020 | 31 | -3 | 0 | 2 | N/A |
| 12/31/2019 | 32 | -4 | -1 | 2 | N/A |
| 9/30/2019 | 31 | -3 | 0 | 2 | N/A |
| 6/30/2019 | 31 | -3 | 2 | 3 | N/A |
| 3/31/2019 | 31 | -3 | 1 | 3 | N/A |
| 12/31/2018 | 30 | -4 | 1 | 3 | N/A |
| 9/30/2018 | 31 | -9 | 2 | 4 | N/A |
| 6/30/2018 | 30 | -22 | 1 | 2 | N/A |
| 3/31/2018 | 31 | -21 | N/A | 3 | N/A |
| 12/31/2017 | 32 | -22 | N/A | 4 | N/A |
| 9/30/2017 | 30 | -18 | N/A | 4 | N/A |
| 6/30/2017 | 31 | -6 | N/A | 4 | N/A |
| 3/31/2017 | 30 | -4 | N/A | 3 | N/A |
| 12/31/2016 | 31 | -3 | N/A | 0 | N/A |
| 9/30/2016 | 33 | -3 | N/A | -1 | N/A |
| 6/30/2016 | 33 | -14 | N/A | -3 | N/A |
| 3/31/2016 | 26 | -22 | N/A | -5 | N/A |
| 12/31/2015 | 18 | -28 | N/A | -7 | N/A |
| 9/30/2015 | 9 | -34 | N/A | -10 | N/A |
| 6/30/2015 | 1 | -24 | N/A | -12 | N/A |
| 3/31/2015 | 1 | -15 | N/A | -14 | N/A |
| 12/31/2014 | 1 | -16 | N/A | -18 | N/A |
| 9/30/2014 | 1 | -14 | N/A | -19 | N/A |
| 6/30/2014 | 1 | -19 | N/A | -20 | N/A |
| 3/31/2014 | 0 | -27 | N/A | -20 | N/A |
| 12/31/2013 | 1 | -26 | N/A | -19 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: SSKN is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: SSKN is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: SSKN is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: SSKN's revenue (7.3% per year) is forecast to grow slower than the US market (8.9% per year).
Ingresos de alto crecimiento: SSKN's revenue (7.3% per year) is forecast to grow slower than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if SSKN's Return on Equity is forecast to be high in 3 years time